Navigation Links
Bioniche Receives Fast Track Designation For First-Line Bladder Cancer Therapy
Date:3/4/2008

- Second Phase III clinical trial to begin later this year -

BELLEVILLE, ON, March 4 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has received notice from the U.S. Food and Drug Administration (FDA) that its therapy for first-line non-muscle-invasive bladder cancer meets the criteria for Fast Track designation. A Phase III clinical trial comparing a formulation of the Company's Mycobacterial Cell Wall-DNA Complex (MCC) - Urocidin(TM) - to the current standard therapy in patients with non-muscle-invasive bladder cancer at high risk of recurrence or progression. This clinical trial, scheduled to begin later in 2008, aims to demonstrate non-inferior efficacy with respect to disease-free survival and fewer toxicities than the current therapy.

This is the second Phase III trial of the Company to receive Fast Track designation: Bioniche's registration trial of Urocidin for bladder cancer patients that have failed current therapies was designated as Fast Track in April, 2006. That first "Refractory" Phase III trial is ongoing at leading bladder cancer centres across Canada and the United States.

The designation of a product/indication as Fast Tracked means that the FDA will take such actions as are appropriate to expedite the development and review of the application for approval of such product. The FDA may also evaluate for filing and commence review of portions of an application for approval of a Fast Track product under certain conditions. The potential for expedited review and the ability to file submission documents on a rolling basis can serve to accelerate final product approval. In its letter of notice, the FDA indicated, "We look forward to working with you to expedite the development and review of this promising proposed use of the product."

"This is an important milestone for our Phase III clinical developmen
'/>"/>

SOURCE Bioniche Life Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Bioniche Pharma Chooses TrackWise for its Deviation Control Solution
2. Bioniche Provides Update on Refractory Bladder Cancer Trial with Urocidin(TM)
3. Bioniche Reports Fiscal 2008 Second Quarter
4. USDA Agrees to Grant Conditional License to Bioniche for its E. coli O157:H7 Cattle Vaccine
5. Bioniche Amends Terms of Convertible Debt with Laurus Master Funds
6. Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario
7. Bioniche Reports Fiscal 2008 First Quarter
8. Bioniche to Present at Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Bioniche Discusses USDA Comment on E. coli O157:H7 Cattle Vaccine Field Trial
10. Bioniche Receives Comment from USDA on a Field Trial for E. coli O157:H7 Cattle Vaccine
11. Bioniche Food Safety Vaccine Receives Global Top Honours in Industry Excellence Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014 This is a ... of the Galactooligosaccharides (GOS) industry in Global ... of the industry, including definitions, applications and industry ... market analysis are provided with a focus on ... market. A comparison between the international and Chinese ...
(Date:7/25/2014)... 25, 2014 Drexel University College of ... MD, MS, FACP, has been appointed vice dean for education, ... Drexel from The Commonwealth Medical College, where she is currently ... clinical affairs, and professor of medicine. , As a ... College, Weber had a major role in many aspects of ...
(Date:7/25/2014)... News) -- Shift workers, especially men, may be at higher ... such schedules, a new study suggests. Also at special ... schedule, with shifts moving around at various times of the ... one expert, Dr. Alan Manevitz, a clinical psychiatrist at Lenox ... known that working shifts disrupts many key body chemicals, creating ...
(Date:7/25/2014)... FRIDAY, July 25, 2014 (HealthDay --, Treatment for lymphoma ... Hodgkin lymphoma and non-Hodgkin lymphoma, which are cancers of ... who are still in their reproductive years. For men, ... production. Although most men regain their fertility within two ... be counseled about the possibility of this significant side ...
(Date:7/25/2014)... new system that sent patients to designated cardiac receiving ... sudden cardiac arrest in Arizona, according to a study ... Medicine . , "We knew lives would be ... guidelines for post-cardiac arrest care and we were able ... to what is done for Level 1 trauma patients," ...
Breaking Medicine News(10 mins):Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 2Health News:GOS Market (Galacto-oligosaccharides) Development in Global & China Regions Now Available at DeepResearchReports.com 3Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 2Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 3Health News:Study Links Shift Work to Risk for Type 2 Diabetes 2Health News:Study Links Shift Work to Risk for Type 2 Diabetes 3Health News:Lymphoma Treatment May Harm, Halt Men's Sperm Production 2Health News:New EMS system in Arizona dramatically improves survival from cardiac arrest 2Health News:New EMS system in Arizona dramatically improves survival from cardiac arrest 3
... A Georgetown University Medical Center (GUMC) scientist who ... frogs and in the dogfish shark has now turned ... dolphins. A dolphin,s ability to heal quickly from ... to infection, hemorrhage protection, and near-restoration of normal body ...
... and Society of Breast Imaging applaud and support updated ... women begin getting annual mammograms at age 40. The ... American Cancer Society, ACR, Society of Breast Imaging (SBI), ... major medical associations with demonstrated expertise in breast cancer ...
... Reporter , WEDNESDAY, July 20 (HealthDay News) -- High-tech helmets ... the force of impact, offering new insight into head and ... help manufacturers design helmets that are more protective, said Steven ... Michigan and lead author of a new report about the ...
... test to distinguish harmless from precancerous pancreatic cysts. ... surgery to remove the harmless variety. A report ... issue of Science Translational Medicine . The ... than a million patients each year, most of whom ...
... News) --, Liars can control certain facial expressions when facing ... a new study shows. The researchers noted the findings ... the study, scientists randomly asked 60 people to either lie ... of movie tickets from an envelope. While being interviewed, the ...
... researchers have developed a new strategy to improve the development ... are created by introducing four defined genes to an adult ... cell, which can differentiate into many different types of the ... Oct4, Sox2, Klf4 and c-Myc, a combination known as OSKM. ...
Cached Medicine News:Health News:Dolphins' 'remarkable' recovery from injury offers important insights for human healing 2Health News:Dolphins' 'remarkable' recovery from injury offers important insights for human healing 3Health News:ACR, SBI support updated ACOG recommendations that women begin annual mammograms at age 40 2Health News:High-Tech Football Helmets Gauge Force of Collision 2Health News:Benign or cancerous? Gene test predicts cancer potential in pancreatic cysts 2Health News:Benign or cancerous? Gene test predicts cancer potential in pancreatic cysts 3Health News:Scrutinizing Faces Might Catch Liars, Study Finds 2Health News:U of M researchers improve method to create induced pluripotent stem cells 2
(Date:7/25/2014)... 25, 2014 /PRNewswire-iReach/ -- Dr. Michael Gabriel of ... reacts to a recent study, which shows how grief in ... http://photos.prnewswire.com/prnh/20140723/129709 According to US ... are more likely than others to grow up overweight or ... There were two specific types of stress that caused ...
(Date:7/24/2014)...  PTC Therapeutics, Inc. (NASDAQ: PTCT ) ... conference call to report its second quarter 2014 financial ... and outlook on Thursday, August 7, 2014 at 8:30 ... The call can be accessed by dialing ... prior to the start of the call and providing ...
(Date:7/24/2014)... , Germany , and ... -- , Exclusive global license ... for SF3B1 mutations, including next-generation sequencing (NGS) gene panels, ... to be targeted by new test, indicate favorable prognosis ... syndromes  QIAGEN sees potential for developing companion ...
Breaking Medicine Technology:Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5
... Dec. 5, 2010 Pfizer Inc. (NYSE: ... has elected Ian C. Read, 57, currently head of ... Officer and Director. Mr. Read succeeds Jeffrey B. Kindler, ... (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) The Board,s Lead Independent Director, ...
... The Infectious Disease Research Institute (IDRI) has ... Advance Research and Development Authority (BARDA). IDRI,s work will ... to $8.5 million over three years when further development ... agency. "BARDA is supporting an important ...
Cached Medicine Technology:Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer 2Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer 3Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer 4IDRI Awarded Contract from BARDA to Develop Next Generation Adjuvants for Pandemic Influenza 2
... an automatic petri dish streaking machine. ... up to 180 pre inoculated petri ... in substantial cost savings. The ISOPLATER® ... standardizes streaking procedures and increases safety ...
Data review and analysis is carried out with the Acquidata Uromac software already supplied with Acquidata Uromac Lab based urodynamics systems...
A compact mobile System Cart gives mobility within your department. The cart accomodates the Uromac Median data processor, desktop computer, printer and provides stowage space. Patient related transd...
... for any clinical setting, offering an ... UDS procedure. Customize Delphis™ to your ... a Pocket PC, a Touchpad PC ... wireless technology allows you to focus ...
Medicine Products: